<DOC>
	<DOC>NCT02633527</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, fixed dose study to assess the efficacy and safety of SPN-812 ER in treatment of children aged 6-12 years with ADHD. The primary objective is to assess the effect of SPN-812 ER in reducing ADHD symptoms. This will be measured using the ADHD-RS-IV rating scale.</brief_summary>
	<brief_title>Efficacy and Safety of SPN-812 ER in Children With ADHD</brief_title>
	<detailed_description />
	<criteria>1. Healthy male or female subjects, 612 years of age, inclusive, with a diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental DisordersIV (DSM IV), confirmed with the Mini International Neuropsychiatric Interview for Children and Adolescents (MINIKID). 2. ADHDRSIVParent Version: Investigator Administered and Scored score of at least 26. 3. CGIS score of at least 4 4. Weight of at least 20 kg. 5. Free of medication for the treatment of ADHD or any psychosis for at least one week prior to enrollment. 1. Current or lifetime diagnosis of major depressive disorder, bipolar disorder, personality disorder, Tourette's disorder, or psychosis not otherwise specified. 2. Currently meeting DSMIV criteria for pervasive developmental disorder, obsessive compulsive disorder, posttraumatic stress disorder, or any other anxiety disorder as primary diagnosis. 3. Significant systemic disease. 4. Evidence of suicidality within the six months before Screening or at Screening. 5. BMI greater than 95th percentile for the appropriate age and gender. 6. Pregnancy or refusal to practice abstinence during the study for female subjects of childbearing potential (FOCP). 7. Substance or alcohol use during the last three months. 8. Positive urine screen for cotinine, alcohol, or drugs of abuse at Screening.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>